Biotechnology
Samsung Biologics' strategic business operations continue to support strong third quarter earnings
INCHEON, South Korea, Oct. 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) maintained steady financial results for its fiscal 2020 third quarter endingSeptember 30, demonstrating confident execution of its ongoing business operations. The Company recorded strong revenues of KRW 274.6...
2020-10-21 19:00
8173
Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment
INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clini...
2020-10-20 19:00
9339
Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing
INCHEON, South Korea, Oct. 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer. Under this agreement, Samsung Biologics will provide a full scope of its ...
2020-10-19 19:00
10240
Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference
* Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year * Cancer is the most common cause of death in dogs over the age of two years old in the U.S. * Togeth...
2020-10-16 20:00
18267
VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced further d...
2020-10-14 20:00
12757
Kanaph Therapeutics Closes 21M USD Series B Funding
SEOUL, South Korea, Oct. 12, 2020 /PRNewswire/ -- Kanaph Therapeutics, a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules, recently completed their Series B funding of21M USD in South Korea. In this round, a large Korean pharma company, GC Pharma...
2020-10-13 11:30
1897
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist
SHANGHAI, Oct. 11, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic ste...
2020-10-12 08:30
7802
Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA
TAIPEI, Oct. 8, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee") announced today that the 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI™ 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the ...
2020-10-09 06:39
2034
EB Research Partnership and EB Research Foundation Come Together as Largest Global Organization Advancing Research for Epidermolysis Bullosa
As the leading EB research funders worldwide, the group will combine to leverage EBRP's innovative business model to accelerate treatments and cures NEW YORK and MELBOURNE, Australia, Oct. 9, 2020 /PRNewswire/ -- EB Research Partnership (EBRP), based inNew York, and EB Research Foundation (EBRF) ...
2020-10-08 21:00
2738
Nagase R&D Center Increases Productivity of Rare Amino Acid "Ergothioneine" 1000-fold: Highest Production Efficiency Reported Using "Smart Cell" Technology
TOKYO, Oct. 7, 2020 /PRNewswire/ -- The Nagase R&D Center, the research and development arm of NAGASE & CO., LTD. based inTokyo, has been developing fermentative production technology for ergothioneine (EGT) (*1) and researching EGT's functions. Using revolutionary biotechnology developed as part...
2020-10-07 14:00
2104
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
SHANGHAI, Oct. 5, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced thatthe United States (US) Food and Drug Administration (FDA) has granted orphan drug designation to one of CARsgen's first-in-class drug candidates, CT041, for the t...
2020-10-05 18:00
5259
Happiness Biotech Announced Receipt of FDA Registration For Its Hand Sanitizer
NANPING, China, Oct. 1, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company's hand sanitizer products have been registered with U.S. Food and Drug Administra...
2020-10-01 22:00
13033
TaiGen Biotechnology Out-Licensed Taigexyn (Nemonoxacin) to Luminarie Canada for Canada, Australia and New Zealand
TAIPEI, Sept. 30, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen")(Taiwan: 4157) today announced that they have signed an exclusive licensing agreement with Luminarie Canada Inc. ("Luminarie"), a leading Canadian pharmaceutical company, to develop and commercialize Taigexyn® ...
2020-09-30 15:51
1859
ILIAS Biologics Closes $20.6 Million Series B Financing
DAEJEON, South Korea, Sept. 28, 2020 /PRNewswire/ -- ILIAS Biologics Inc. (the "Company" or "ILIAS"), a leading exosome-based therapeutics company, announced today that the Company has completed a Series B financing round of$20.6 million inSouth Korea. The initial investors from the Series A rou...
2020-09-28 19:00
1716
World's first clinical trial of non-viral PD1 specific targeted CAR T therapy achieves great breakthroughs
SHANGHAI, Sept. 28, 2020 /PRNewswire/ -- On September 25, 2020, BIORAY LABORATORIES Inc. ("Bioraylab"), a company specialized in gene therapy and cell drug R&D, announced for the first time that clinical trials of non-viral PD1 specific targeted CAR T therapy in relapsed/refractory B-cell non-Hod...
2020-09-28 19:00
1590
Carmine Therapeutics named as one of FierceBiotech's "Fierce 15" Biotech Companies of 2020
CAMBRIDGE, Mass., Sept. 28, 2020 /PRNewswire/ -- Carmine Therapeutics announced today that it has been named by FierceBiotech as one of 2020's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The 2020 Fierce 15 com...
2020-09-28 18:00
1439
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA
NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary O...
2020-09-25 10:37
2323
KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development
SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has...
2020-09-24 17:12
1745
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital
SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing ofUS$10 million Series B Plus strategic financing. This round of financing wi...
2020-09-24 00:09
2178
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
* Minoryx will receive an upfront and milestone payments of up to $78 million , as well as double digit royalties on annual net sales * Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-th...
2020-09-23 15:00
1548
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116